SoftOx Solutions is trading at NOK 0.09, down -7.06%; the reason remains unclear pending possible delayed disclosure.
- No new company-specific announcement or credible catalyst was identified for August 26, 2026.
- The latest public development remains the August 11 first-patient dosing in the SIS-03 proof-of-concept trial, not a new event today.
- Broader biotech sentiment is positive, but that sector move does not explain the decline.